Abstract:
Osteoporosis is a systemic skeletal condition characterized by decreased bone strength with consequent increased susceptibility to bone fracture. Fragility fractures in osteoporosis are often painful and result in loss of quality of life and disability. Salmon calcitonin (SCT) is a natural hormone that may assist in the management of osteoporotic patients following fracture by reducing fracture risk and decreasing pain. SCT is an antiresorptive agent which has been shown to reduce the risk of vertebral fractures (by 36%) in postmenopausal women with osteoporosis and previous fractures, with a safety profile comparable to placebo over long-term use. Clinical evidence suggests that SCT (with either subcutaneous and intranasal delivery) is an analgesic for the acute pain following osteoporotic fracture. Pain relief with SCT occurs after 1 week or less of treatment. Associated with this pain relief, vertebral fracture patients receiving SCT have been observed to have earlier mobilization compared with those receiving a placebo. Both preclinical and clinical data suggest a central analgesic effect for SCT. The mechanism(s) by which SCT induces pain relief has (have) not been conclusively shown. Neither a direct receptor-mediated action nor an indirect endorphin-mediated effect can be ruled out.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 26 October 2001 / Accepted: 17 June 2002
Correspondence and offprint requests to: Stuart Silverman, MD, 8641 Wilshire Blvd, Suite 301, Beverly Hills, CA 90211, USA. e-mail: stuarts@omcresearch.org
Rights and permissions
About this article
Cite this article
Silverman, S., Azria, M. The Analgesic Role of Calcitonin Following Osteoporotic Fracture . Osteoporos Int 13, 858–867 (2002). https://doi.org/10.1007/s001980200118
Issue Date:
DOI: https://doi.org/10.1007/s001980200118